Francesco Scarlata

Francesco Scarlata

Auto-generated profile, based on publicly available information

Francesco Scarlata

Department of Sciences for Health Promotion and Mother and Child Care “G. D’Alessandro”, University of Palermo, Via del Vespro 133, 90127 Palermo, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2006 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
Claudia ColombaClaudia Colomba
Claudia Colomba
Simona De GraziaSimona De Grazia
Simona De Grazia
Giovanni M. GiammancoGiovanni M. Giammanco
Giovanni M. Giammanco
LSL. Saporito
L. Saporito
FSF. Scarlata
F. Scarlata
SAS. Arista
S. Arista

1 April 2008 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
FSFrancesco Scarlata
Francesco Scarlata
Fabrizio VitaleFabrizio Vitale
Fabrizio Vitale
LSLaura Saporito
Laura Saporito
SRStefano Reale
Stefano Reale
VVValentina Li Vecchi
Valentina Li Vecchi
LTLucina Titone
Lucina Titone
The purpose of this study was to evaluate whether the risk of transfusion-transmitted visceral leishmaniasis was present in an area of western Sicily where the incidence of the disease is higher than the regional average. From May to December 2005, 1449 blood donors from Agrigento district (Sicily, Italy) were screened for the presence of anti-Leishmania antibodies by an indirect immunofluorescent antibody test (IFAT). Blood samples from IFAT-positive donors were examined by PCR to detect Leishmania DNA. Anti-Leishmania antibodies were found in 11 (0.75%) cases, among which Leishmania DNA was detected from four (36.4%). Particular techniques to inactivate different pathogens would be considered mandatory in the case of immunosuppressed recipients.

1 July 1997 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
Antonio CascioAntonio Cascio
Antonio Cascio
LGLuigi Gradoni
Luigi Gradoni
FSFrancesco Scarlata
Francesco Scarlata
MGMarina Gramiccia
Marina Gramiccia
SGSalvatore Giordano
Salvatore Giordano
LTLucina Titone
Lucina Titone
Visceral leishmaniasis (VL) is endemic in Sicily. Although it is a notifiable disease, there is evidence that the actual number of cases is higher than that reported. In 1987, a regional reference center for active surveillance of VL was established and it recorded a total of 284 cases through 1995, a mean of 31.5 cases/year and about four-fold more than previously reported. Of the 284 cases, 150 (53%) were children (≤ 14 years of age), and of the 134 adults, 39 (29%) were coinfected with human immunodeficiency virus (HIV). The commonest viscerotropic zymodeme of Leishmania infantum, MON 1, was identified in 40 (93%) of 43 HIV-negative and eight (57%) of 14 HIV-positive patients. Among 280 patients evaluated (i.e., all HIV-negative and 35 of 39 HIV-positive subjects), 254 (91%) were treated with meglumine antimoniate alone or in combination with other drugs; 23 (8%) received allopurinol or amphotericin B, either conventional or in liposomal form; and three terminally ill patients were not treated. Among the 245 HIV-negative patients, 236 (96%) were successfully cured, while nine (4%) (seven adults) died during the course of antimonial treatment. None of the 35 HIV-positive patients was definitively cured, although mortality was apparently associated with other opportunistic infections.

15 June 2003 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
Manlio TolomeoManlio Tolomeo
Manlio Tolomeo
Paola Di CarloPaola Di Carlo
Paola Di Carlo
VAV. Abbadessa
V. Abbadessa
LTL. Titone
L. Titone
SMS. Miceli
S. Miceli
FSF. Scarlata
F. Scarlata
This study evaluated the level of susceptibility of monocytes and lymphocytes to spontaneously induced and CH11-induced apoptosis in 16 patients with Brucella infection. The expression of some immunological and apoptotic markers was evaluated. Before therapy, monocytes showed a high level of resistance to spontaneously induced or CH11-induced apoptosis in all patients. In patients with acute infection, this resistance persisted for 10–20 days after treatment was initiated, then decreased; in chronically infected patients, it persisted after 45 days of treatment. Lymphocytes were also more resistant to CH11-induced apoptosis. The level of activated CD8+ T lymphocytes was high in patients with acute infection. The data indicate that the CD95-mediated apoptotic pathway is not involved in CH11 resistance. Lymphocytes are not infected by Brucella, so their resistance to apoptosis may be due to a soluble factor released by infected monocytes. The evaluation of levels of susceptibility to CH11-induced apoptosis in monocytes may be used to test the effectiveness of the therapy.

1 June 2012 in Emerging Infectious Diseases
Verified
Journal Article
Open access
ATAlessandra Torina
Alessandra Torina
IFIsabel G. Fernández-De-Mera
Isabel G. Fernández-De-Mera
AAAngelina Alongi
Angelina Alongi
AMAtilio J. Mangold
Atilio J. Mangold
Valeria BlandaValeria Blanda
Valeria Blanda
Jose De La FuenteJose De La Fuente
Jose De La Fuente
R. conorii and R. slovaca, Sicily

1 July 2004 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
Antonio CascioAntonio Cascio
Antonio Cascio
CLChiara Di Liberto
Chiara Di Liberto
MDMatteo D'Angelo
Matteo D'Angelo
CIChiara Iaria
Chiara Iaria
FSFrancesco Scarlata
Francesco Scarlata
Giuseppina CampisiGiuseppina Campisi
Giuseppina Campisi